Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Inclusion Criteria: Patients must meet all of the following criteria at Baseline: * Patients initiating Hyrimoz® treatment. * Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC. * Patients ≥ 18 years of age. * Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study. * Patients meeting one of the following criteria: * Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria). * Referred to as "biologic-naive patients": Patients who had an inadequate response or contraindications to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a first-line biologic therapy according to the summary of product characteristics (SmPC). * Patients able to complete and understand the self-administered questionnaires. * Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for inclusion in this study: * Patients enrolled in an ongoing interventional study. * Patients with any contraindications to Hyrimoz® according to the SmPC. * Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula). * Use of any investigational drug in last 6 months prior to enrollment. * Patient received any biological medicine or targeted therapy, in case of " biologic-naive patient ", * Patient received adalimumab for less than 6 months or have controlled disease for less than 3 months, in case of "switched patient".